Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 2/20 | 0.66 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.66 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.66 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.66 |
| ▸ | DGKA | P23743 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.55 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.55 |
| ▸ | LPAR4 | Q99677 | 2/20 | 0.55 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.55 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.55 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.55 |
| ▸ | CES2 | O00748 | 1/20 | 0.55 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylamine SCHEMBL20573406 | 1.00 | PRKCA (0.66) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL21388171 | 0.96 | PRKCA (0.71) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL12900884 | 0.96 | PRKCA (0.71) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL15788629 | 0.96 | PRKCA (0.71) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL7784995 | 0.96 | PRKCA (0.71) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| Ammonia Solution, Strong SCHEMBL1504312 | 0.94 | PRKCA (0.69) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| Ammonia Solution, Strong SCHEMBL10973596 | 0.94 | PRKCA (0.69) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| Trimethylammonium SCHEMBL21381517 | 0.92 | PRKCA (0.66) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| Ethylene Glycol SCHEMBL1715383 | 0.92 | PRKCA (0.70) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| Trimethylammonium SCHEMBL1301984 | 0.92 | PRKCA (0.66) | PRKCAPRKCEPRKCQPRKCDDGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1656 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116845-A1 | LIPIDS AND COMPOSITIONS THEREOF | KERNAL BIOLOGICS INC (US) | 2026-04-30 | — | — | US | claimed |
| EP-4321504-B1 | PEGYLATED LIPID AND LIPOSOME MODIFIED THEREBY, AND PHARMACEUTICAL COMPOSITION COMPRISING LIPOSOME AND PREPARATION AND USE THEREOF | XIAMEN SINOPEG BIOTECH CO LTD (CN) | 2026-02-18 | — | — | EP | claimed |
| EP-4695401-A1 | SYNTHETIC CIRCUITS AND USES THEREOF | Strand Therapeutics Inc. (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4652281-A2 | GENE EDITING FOR SURGERY-RELATED FIBROSIS TREATMENT | Orthobio Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | claimed |
| EP-4036079-B1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2025-11-19 | — | — | EP | claimed |
| US-12414918-B2 | Pharmaceutical composition of lipid nanoparticle for delivering nucleic acid drug containing trehalose derivative and novel structure-maintaining lipid compound | SML BIOPHARM CO., LTD. (KR) | 2025-09-16 | — | — | US | claimed |
| US-20250263681-A1 | LIPID NANOPARTICLES FOR GENE EDITING SYSTEMS | ORTHOBIO THERAPEUTICS INC (US) | 2025-08-21 | — | — | US | claimed |
| US-20250228969-A1 | GENE EDITING TO IMPROVE JOINT FUNCTION | ORTHOBIO THERAPEUTICS, INC. | 2025-07-17 | — | — | US | claimed |
| WO-2025133684-A1 | LIPOSOMAL NANOPARTICLES FOR CRISPR/CAS9 DELIVERY | VILNIUS UNIVERSITY (LT) | 2025-06-26 | — | — | WO | claimed |
| US-20250161494-A1 | TRANSMEMBRANE RECEPTOR GENE EDITING | ORTHOBIO THERAPEUTICS INC (US) | 2025-05-22 | — | — | US | claimed |
| WO-2017201348-A1 | POLYNUCLEOTIDES ENCODING GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE FOR THE TREATMENT OF GALACTOSEMIA TYPE 1 | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | claimed |
| WO-2017201349-A1 | POLYNUCLEOTIDES ENCODING CITRIN FOR THE TREATMENT OF CITRULLINEMIA TYPE 2 | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | claimed |
| WO-2017201347-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | claimed |
| WO-2017201346-A1 | POLYNUCLEOTIDES ENCODING PORPHOBILINOGEN DEAMINASE FOR THE TREATMENT OF ACUTE INTERMITTENT PORPHYRIA | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | claimed |
| WO-2017201328-A1 | POLYNUCLEOTIDES ENCODING α-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | claimed |
| WO-2017201333-A1 | POLYNUCLEOTIDES ENCODING LIPOPROTEIN LIPASE FOR THE TREATMENT OF HYPERLIPIDEMIA | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | claimed |
| US-20170273907-A1 | STABLE FORMULATIONS OF LIPIDS AND LIPOSOMES | BIONTECH RNA PHARMACEUTICALS GMBH (DE) | 2017-09-28 | — | — | US | claimed |
| WO-2017127750-A1 | MESSENGER RIBONUCLEIC ACIDS FOR THE PRODUCTION OF INTRACELLULAR BINDING POLYPEPTIDES AND METHODS OF USE THEREOF | MODERNATX, INC. (US) | 2017-07-27 | — | — | WO | claimed |
| WO-2017112865-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2017-06-29 | — | — | WO | claimed |
| WO-2017049245-A2 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2017-03-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161494-A1 | TRANSMEMBRANE RECEPTOR GENE EDITING | LDLR, NGFR, APLNR | PRKCA 473/4885PRKCE 692/4885PRKCQ 592/4885 |
| US-12414918-B2 | Pharmaceutical composition of lipid nanoparticle for delivering nucleic acid drug containing trehalose derivative and novel structure-maintaining lipid compound | RNMT, RPN2, DDOST | PRKCA 2457/4885PRKCE 4136/4885PRKCQ 2801/4885 |
| US-20250228969-A1 | GENE EDITING TO IMPROVE JOINT FUNCTION | ROS1, SYVN1, ATF4 | PRKCA 102/4885PRKCE 333/4885PRKCQ 191/4885 |
| US-20260116845-A1 | LIPIDS AND COMPOSITIONS THEREOF | LIPC, LIPA, NPC1L1 | PRKCA 1792/4885PRKCE 2005/4885PRKCQ 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.